China
Chase Sun
Service category:
Trading Companies
Payment:
Service types:
Description
Tianjin Chase Sun Pharmaceutical Co., Ltd. is a listed pharmaceutical company with market value of over RMB 10 billion. After over 2 decades of arduous efforts, it has become a high-tech pharmaceutical health industry cluster that covers TCM granules, finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services and other areas, and integrates financing, manufacturing, R&D and sales. The business’s in possession of more than 50 affiliates and over 6,000 employees. In recent years, the business received numerous honorary titles of National High-Tech Enterprise, National Center for Enterprise Technology, National Technology Innovation Demonstration Enterprise, National & Local Joint Engineering Research Center and etc. Since 2015, the company has been ranked among the Top 100 Enterprises in China’s Pharmaceutical Industry.
Scientific and technological innovation has been the core driving force of sustainable development of Chase Sun, and the business has long built technology transfer center, academician workstation as well as innovation alliance with numerous research institutes, which are designed to realize the dream of industrialization of scientists’ research results and let them benefit the public based on scientific research. For many years, Chase Sun has been focusing on researches and innovations in the five drug areas of critical, neoplastic, cardio-cerebrovascular, respiratory and neurodegenerative diseases, and dedicated to reducing China’s ICU fatality rate. It has already developed ace product catalog with independent IPRs represented by Xuebijing® injection and other first-aid medicines for critical diseases. A paper on RCT for Xuebijing’s Efficacy in Treatment of SCAP was published on the authoritative international critical medicine journal of Critical Care Medicine (CCM) in 2019 with corresponding authors of Prof. Bai Chunxue, Zhongshan Hospital, Fudan University and Shang Hongcai, Research Fellow of Dongzhimen Hospital, Beijing University of Chinese Medicine as well as first author of Prof. Song Yuanlin, Zhongshan Hospital, Fudan University. According to research, Xuebijing®reduced fatality rate of patients with severe pneumonia by 8.8%, made significant breakthrough in research methodology for evidence-based traditional Chinese medicine, reflected concrete clinical value of reduction of fatality rate of critical diseases, and created a new treatment pattern featured by combined use of Chinese and western medicine for patients with critical diseases. Chase Sun has got around 400 valid patents at the moment, and it will introduce dozens of new drugs reserved into the market
Scientific and technological innovation has been the core driving force of sustainable development of Chase Sun, and the business has long built technology transfer center, academician workstation as well as innovation alliance with numerous research institutes, which are designed to realize the dream of industrialization of scientists’ research results and let them benefit the public based on scientific research. For many years, Chase Sun has been focusing on researches and innovations in the five drug areas of critical, neoplastic, cardio-cerebrovascular, respiratory and neurodegenerative diseases, and dedicated to reducing China’s ICU fatality rate. It has already developed ace product catalog with independent IPRs represented by Xuebijing® injection and other first-aid medicines for critical diseases. A paper on RCT for Xuebijing’s Efficacy in Treatment of SCAP was published on the authoritative international critical medicine journal of Critical Care Medicine (CCM) in 2019 with corresponding authors of Prof. Bai Chunxue, Zhongshan Hospital, Fudan University and Shang Hongcai, Research Fellow of Dongzhimen Hospital, Beijing University of Chinese Medicine as well as first author of Prof. Song Yuanlin, Zhongshan Hospital, Fudan University. According to research, Xuebijing®reduced fatality rate of patients with severe pneumonia by 8.8%, made significant breakthrough in research methodology for evidence-based traditional Chinese medicine, reflected concrete clinical value of reduction of fatality rate of critical diseases, and created a new treatment pattern featured by combined use of Chinese and western medicine for patients with critical diseases. Chase Sun has got around 400 valid patents at the moment, and it will introduce dozens of new drugs reserved into the market
User's comments